Literature DB >> 33686245

Aristolochic acid I promoted clonal expansion but did not induce hepatocellular carcinoma in adult rats.

Yong-Zhen Liu1,2, Heng-Lei Lu1,2, Xin-Ming Qi2, Guo-Zhen Xing2, Xin Wang2, Pan Yu2, Lu Liu2, Fang-Fang Yang2, Xiao-Lan Ding2, Ze-An Zhang1, Zhong-Ping Deng3, Li-Kun Gong4,5, Jin Ren6.   

Abstract

Aristolochic acid I (AAI) is a well-known nephrotoxic carcinogen, which is currently reported to be also associated with hepatocellular carcinoma (HCC). Whether AAI is a direct hepatocarcinogen remains controversial. In this study we investigated the association between AAI exposure and HCC in adult rats using a sensitive rat liver bioassay with several cofactors. Formation of glutathione S-transferase placental form-positive (GST-P+) foci was used as the marker for preneoplastic lesions/clonal expansion. We first conducted a medium-term (8 weeks) study to investigate whether AAI had any tumor-initiating or -promoting activity. Then a long-term (52 weeks) study was conducted to determine whether AAI can directly induce HCC. We showed that oral administration of single dose of AAI (20, 50, or 100 mg/kg) in combination with partial hepatectomy (PH) to stimulate liver proliferation did not induce typical GST-P+ foci in liver. In the 8-week study, only high dose of AAI (10 mg · kg-1 · d-1, 5 days a week for 6 weeks) in combination with PH significantly increased the number and area of GST-P+ foci initiated by diethylnitrosamine (DEN) in liver. Similarly, only high dose of AAI (10 mg· kg-1· d-1, 5 days a week for 52 weeks) in combination with PH significantly increased the number and area of hepatic GST-P+ foci in the 52-week study. No any nodules or HCC were observed in liver of any AAI-treated groups. In contrast, long-term administration of AAI (0.1, 1, 10 mg· kg-1· d-1) time- and dose-dependently caused death due to the occurrence of cancers in the forestomach, intestine, and/or kidney. Besides, AAI-DNA adducts accumulated in the forestomach, kidney, and liver in a time- and dose-dependent manner. Taken together, AAI promotes clonal expansion only in the high-dose group but did not induce any nodules or HCC in liver of adult rats till their deaths caused by cancers developed in the forestomach, intestine, and/or kidney. Findings from our animal studies will pave the way for further large-scale epidemiological investigation of the associations between AA and HCC.
© 2021. The Author(s), under exclusive licence to CPS and SIMM.

Entities:  

Keywords:  DNA adducts; aristolochic acid I; clonal expansion; glutathione S-transferase placental form-positive foci; hepatocellular carcinoma; medium-term rat liver bioassay

Mesh:

Substances:

Year:  2021        PMID: 33686245      PMCID: PMC8633323          DOI: 10.1038/s41401-021-00622-7

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   7.169


  67 in total

1.  Effect of aristolochic acid on intracellular calcium concentration and its links with apoptosis in renal tubular cells.

Authors:  Yi-Hong Hsin; Chi-Hung Cheng; Jason T C Tzen; Ming-Ju Wu; Kuo-Hsiung Shu; Hong-Chen Chen
Journal:  Apoptosis       Date:  2006-12       Impact factor: 4.677

Review 2.  A systematic review of the possible carcinogenic role of the aristolochic acid.

Authors:  Tivadar Bara; Simona Gurzu; Haruhiko Sugimura; Tivadar Bara; Marius Alexandru Beleaua; Ioan Jung
Journal:  Rom J Morphol Embryol       Date:  2017       Impact factor: 1.033

3.  Aristolochic acid-associated urothelial cancer in Taiwan.

Authors:  Chung-Hsin Chen; Kathleen G Dickman; Masaaki Moriya; Jiri Zavadil; Viktoriya S Sidorenko; Karen L Edwards; Dmitri V Gnatenko; Lin Wu; Robert J Turesky; Xue-Ru Wu; Yeong-Shiau Pu; Arthur P Grollman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-09       Impact factor: 11.205

4.  Activating mutations at codon 61 of the c-Ha-ras gene in thin-tissue sections of tumors induced by aristolochic acid in rats and mice.

Authors:  H H Schmeiser; H R Scherf; M Wiessler
Journal:  Cancer Lett       Date:  1991-08       Impact factor: 8.679

5.  TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours.

Authors:  Tatiana Nedelko; Volker M Arlt; David H Phillips; Monica Hollstein
Journal:  Int J Cancer       Date:  2009-02-15       Impact factor: 7.396

6.  Vitamin C attenuates the toxic effect of aristolochic acid on renal tubular cells via decreasing oxidative stress‑mediated cell death pathways.

Authors:  Tsai-Kun Wu; Chyou-Wei Wei; Ying-Ru Pan; Shur-Hueih Cherng; Wei-Jung Chang; Hsueh-Fang Wang; Yung-Luen Yu
Journal:  Mol Med Rep       Date:  2015-08-03       Impact factor: 2.952

7.  Preventing aristolochic acid nephropathy.

Authors:  Nelomi Anandagoda; Graham M Lord
Journal:  Clin J Am Soc Nephrol       Date:  2015-01-13       Impact factor: 8.237

8.  The impact of p53 on aristolochic acid I-induced nephrotoxicity and DNA damage in vivo and in vitro.

Authors:  Mateja Sborchia; Eric G De Prez; Marie-Hélène Antoine; Lucie Bienfait; Radek Indra; Gabriel Valbuena; David H Phillips; Joëlle L Nortier; Marie Stiborová; Hector C Keun; Volker M Arlt
Journal:  Arch Toxicol       Date:  2019-10-10       Impact factor: 5.153

9.  Induction of cytochromes P450 1A1 and 1A2 suppresses formation of DNA adducts by carcinogenic aristolochic acid I in rats in vivo.

Authors:  Helena Dračínská; František Bárta; Kateřina Levová; Alena Hudecová; Michaela Moserová; Heinz H Schmeiser; Klaus Kopka; Eva Frei; Volker M Arlt; Marie Stiborová
Journal:  Toxicology       Date:  2016-02-01       Impact factor: 4.221

10.  The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1.

Authors:  Moko Zeniya; Takayasu Mori; Naofumi Yui; Naohiro Nomura; Shintaro Mandai; Kiyoshi Isobe; Motoko Chiga; Eisei Sohara; Tatemitsu Rai; Shinichi Uchida
Journal:  Sci Rep       Date:  2017-10-12       Impact factor: 4.379

View more
  2 in total

1.  Integration of Transcriptomic and Metabolomic Data to Compare the Hepatotoxicity of Neonatal and Adult Mice Exposed to Aristolochic Acid I.

Authors:  Zhi-E Fang; Chunyu Wang; Ming Niu; Tingting Liu; Lutong Ren; Qiang Li; Zhiyong Li; Ziying Wei; Li Lin; Wenqing Mu; Yuan Gao; Xiaohe Xiao; Zhaofang Bai
Journal:  Front Genet       Date:  2022-03-25       Impact factor: 4.599

2.  Asari Radix et Rhizoma consumption lacks relevance for hepatocellular carcinoma in patients: A retrospective cohort study.

Authors:  Zhi-E Fang; Yuming Guo; Zhilei Wang; Tingting He; Jiabo Wang; Zhaofang Bai; Xiaohe Xiao
Journal:  Chin Herb Med       Date:  2022-03-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.